|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||377.418 g/mol g·mol−1|
|3D model (JSmol)|
Selurampanel (INN, code name BGG492) is a drug closely related to the quinoxalinedione series which acts as a competitive antagonist of the AMPA and kainate receptors and, as of 2015, is being investigated in clinical trials by Novartis for the treatment of epilepsy. It has also been studied in the acute treatment of migraine, and was found to produce some pain relief, but with a relatively high rate of side effects.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|